MetaVia Inc. (NASDAQ:MTVA) Short Interest Update

MetaVia Inc. (NASDAQ:MTVA) was the recipient of a large decrease in short interest in July. As of July 31st, there was short interest totaling 160,464 shares, a decrease of 53.4% from the July 15th total of 344,566 shares. Currently, 3.1% of the company’s shares are sold short. Based on an average daily volume of 100,346 shares, the days-to-cover ratio is currently 1.6 days.

MetaVia Stock Performance

Shares of NASDAQ MTVA traded down $0.01 during midday trading on Monday, reaching $1.49. 52,204 shares of the company’s stock were exchanged, compared to its average volume of 1,678,326. MetaVia has a 52-week low of $0.97 and a 52-week high of $19.03. The business’s fifty day moving average price is $1.60 and its two-hundred day moving average price is $1.69. The stock has a market capitalization of $7.66 million, a PE ratio of -0.46 and a beta of 0.95.

MetaVia (NASDAQ:MTVA) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08). Analysts predict that MetaVia will post -2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on MTVA. Wall Street Zen raised shares of MetaVia to a “sell” rating in a research report on Saturday, June 20th. HC Wainwright reiterated a “buy” rating on shares of MetaVia in a report on Friday, July 10th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a research report on Tuesday, July 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $20.00.

Institutional Trading of MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC purchased a new stake in MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia as of its most recent filing with the SEC. Institutional investors and hedge funds own 1.37% of the company’s stock.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.